Additionally, tarlatamab (AMG 757), a bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3) and CD3, demonstrated preliminary efficacy and safety in recurrent SCLC, with an ORR of 23.4%, median PFS of 3.7 months, and median OS of 13.2 months (Paz-Ares et al., 2023). This evidence concerns the gene DLL3 and small cell lung carcinoma.